Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence

被引:28
作者
Campbell, Ulka B. [1 ]
Stang, Paul [1 ]
Barron, Rich [2 ]
机构
[1] Cerner Galt, New York, NY 10003 USA
[2] Allergan Corp Inc, Irvine, CA USA
关键词
compliance; drug therapy; survey; treatment efficacy; urinary incontinence;
D O I
10.1111/j.1524-4733.2007.00295.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Purpose: To evaluate treatment satisfaction and compliance with pharmacologic therapy in urinary incontinence patients. Materials and Methods: An online survey was returned by 1447 individuals from a nationwide panel of adults who had previously reported treatment for incontinence symptoms and agreed to participate in survey research. Data on demographics, incontinence severity, treatment compliance, and satisfaction were obtained. Logistic regression was used to estimate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for characteristics associated with pharmacologic treatment dissatisfaction and discontinuation. Results: The sample was predominantly female (87%) and white (93%) with a mean age of 56 years. On average, patients urinated 10 times/day and experienced 16 wetting accidents in the week preceding survey. Overall, 25% reported being somewhat or very dissatisfied with treatment. Those who reported a severe effect of incontinence on their lives were most likely to be dissatisfied (OR = 2.82, 95% CI = 1.89-4.23). Discontinuation of drug treatment was reported by 45% of study subjects, with major reasons being poor efficacy (in 41.3% of discontinuations), side effects (22.4%), and cost (18.7%). Predictors for discontinuation included young age (OR = 1.8, 95% CI = 1.2-2.8), experiencing symptoms for 10 or more years (OR = 1.5, 95% CI = 1.1-2.0), and experiencing more than 16 wetting accidents in the last week (OR = 1.6, 95% CI = 1.3-2.1). Conclusions: This online survey of self-selected incontinence patients indicated that almost half of those who have received drug treatment for incontinence had discontinued primarily because of lack of efficacy, side effects, and cost concerns. Our findings suggest a substantial degree of unmet need from current therapy among those with incontinence.
引用
收藏
页码:726 / 732
页数:7
相关论文
共 34 条
  • [1] Abrams P, 1998, BRIT J UROL, V81, P801
  • [2] Twelve-month treatment of overactive bladder - Efficacy and tolerability of tolterodine
    Abrams, P
    Malone-Lee, J
    Jacquetin, B
    Wyndaele, JJ
    Tammela, T
    Jonas, U
    Wein, A
    [J]. DRUGS & AGING, 2001, 18 (07) : 551 - 560
  • [3] [Anonymous], 1996, AHCPR PUBLICATION
  • [4] [Anonymous], UROLOGY
  • [5] Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
    Appell, RA
    [J]. UROLOGY, 1997, 50 (6A) : 90 - 96
  • [6] Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine
    Appell, RA
    Abrams, P
    Drutz, HP
    Van Kerrebroeck, PEVA
    Millard, R
    Wein, A
    [J]. WORLD JOURNAL OF UROLOGY, 2001, 19 (02) : 141 - 147
  • [7] Barron RL, 2005, QUAL LIFE RES, V14, P2144
  • [8] BOCCUZZI SJ, 2002, VALUE HEALTH, V5, P274
  • [9] Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder
    Chapple, CR
    Rechberger, T
    Al-Shukri, S
    Meffan, P
    Everaert, K
    Huang, M
    Ridder, A
    [J]. BJU INTERNATIONAL, 2004, 93 (03) : 303 - 310
  • [10] Patient persistency with medications for overactive bladder
    Chui, MA
    Williamson, T
    Arciniega, J
    Thompson, C
    Benecke, H
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 366 - 366